The Challenge

A global pharma market access organization draws on payer data vendors, claims and finance systems, hubs and speciality pharmacies, and evidence from trials, real-world sources and economic models. The data exists. Getting it to mean the same thing to payers, finance and analytics is the problem, and EU joint clinical assessments, which began for oncology medicines and advanced therapies in January 2025, raise the bar for consistent, traceable evidence.

Key Challenges Included:

  • Every Vendor Describes the Payer Landscape Differently. Payers, plans, PBMs and parent organizations are named and grouped differently by each provider, coverage is not tied to commercial product definitions, and every refresh restarts the reconciliation.
  • Contracts, Claims and Finance Disagree on Product and Metric. Product, pack and gross-to-net definitions differ between access, finance and analytics, so net revenue variances are hard to explain.
  • Evidence Without a Traceable Trail. Indications, endpoints and outcomes are coded differently across trial, real-world and economic inputs, and tracing a dossier claim back to its data and definitions is manual.
  • Launch Analytics and GenAI Without Shared Payer Meaning. Hubs and speciality pharmacies use local labels, coverage and uptake are hard to relate, and conversational tools give inconsistent answers.

Our Solution

A Governed Access Ontology, Defined Once and Reused Across Launches

1
Democratized Data Access
Developed a non-SQL method for querying data within the EDF, eliminating the need for SQL knowledge.

Pre-Modeled Payer and Metric Vocabulary
‍
Market access and payer concepts, metrics and KPIs from the Agilisium Pharma Commercial Pack, with NAICS, RxNorm, NUCC, CMS NPPES and US Census geography as reference standards.

2

AI-Assisted Alignment with Human Approval
‍
Vendor and partner feeds profiled and proposed for alignment to the shared model; analysts and program owners review and approve, so each refresh builds on earlier mappings.

3

Shared Product and Metric Definitions
‍
Product concepts anchored to RxNorm and gross-to-net and other metrics defined once as approved, versioned semantic metrics. AOMP governs the definitions; it does not calculate rebates.

4

Evidence Anchored to Shared Concepts, with Provenance
‍
Indications, endpoints and outcomes anchored to NCIt, MONDO, LOINC, UCUM and RxNorm (SNOMED CT where licensed), with lineage connecting definitions to the data and approvals behind them.

5

Grounded Launch Analytics and AI
‍
Coverage, claims and sales bound to shared payer and product concepts, business-language questions answered with provenance, and ontology context provided to AI agents through APIs and MCP.

Key Impact
1
Governed access ontology reused across vendors, launches, dossiers and AI agents
$416B
Estimated manufacturer gross-to-net reductions on US brand-name drugs in 2025, the scale of definitions to govern
The Customer
A large pharmaceutical access organization preparing multi-market launches. End users include the VP Market Access, Head of Payer Strategy, Head of Pricing and Contracting, HEOR and Value and Evidence leads, Patient Access and Services, and Access Analytics teams.

The Outcomes

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

One Payer Landscape, Many Vendors
C
onsistent payer and plan views across vendors, with less reconciliation per data refresh.

Same Product, Same Metric, Same Number
‍
Access, sales and finance analyze contracts and net revenue on one product and metric basis, and definition changes are visible across periods.

Evidence Payers Can Scrutinize
‍
Trial, real-world and economic inputs line up on shared concepts, with definitions traceable to data and approvals.

Launch-Ready Reuse
‍
Semantic assets built for one launch are reused for the next, and routine access questions depend less on analyst time.

Recent Case Studies

Case study
Transforming datamanagement in a leadingpharmaceutical company withdata lens
Case study
Transforming data Transforming Biotech Field Operations: Enhancing Efficiency and Accuracy with Doc Sonar, a Gen Al-Driven Solution
Read more
Case study
Transforming datamanagement in a leadingpharmaceutical company withdata lens
Case study
Transforming data Transforming Biotech Field Operations: Enhancing Efficiency and Accuracy with Doc Sonar, a Gen Al-Driven Solution
Read more
Case study
Transforming datamanagement in a leadingpharmaceutical company withdata lens
Case study
Transforming data Transforming Biotech Field Operations: Enhancing Efficiency and Accuracy with Doc Sonar, a Gen Al-Driven Solution
Read more
Case study
Transforming datamanagement in a leadingpharmaceutical company withdata lens
Case study
Transforming data Transforming Biotech Field Operations: Enhancing Efficiency and Accuracy with Doc Sonar, a Gen Al-Driven Solution
Read more